Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
45
ALNY Quote, Financials, Valuation and Earnings
Last price:
$406.32
Seasonality move
:
1.76%
Day range:
$383.84 - $400.00
52-week range:
$205.87 - $495.55
Dividend yield:
0%
P/E ratio:
1,654.18x
P/S ratio:
16.32x
P/B ratio:
224.71x
Volume:
1.1M
Avg. volume:
1.5M
1-year change:
69.81%
Market cap:
$52.6B
Revenue:
$2.2B
EPS (TTM):
$0.24
Analysts' Opinion
-
Consensus RatingAlnylam Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $491.92, Alnylam Pharmaceuticals, Inc. has an estimated upside of 23.65% from its current price of $397.83.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $310.00 representing 100% downside risk from its current price of $397.83.
Fair Value
-
According to the consensus of 21 analysts, Alnylam Pharmaceuticals, Inc. has 23.65% upside to fair value with a price target of $491.92 per share.
ALNY vs. S&P 500
-
Over the past 5 trading days, Alnylam Pharmaceuticals, Inc. has underperformed the S&P 500 by -1.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Alnylam Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Alnylam Pharmaceuticals, Inc. has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Alnylam Pharmaceuticals, Inc. reported revenues of $1.2B.
Earnings Growth
-
Alnylam Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Alnylam Pharmaceuticals, Inc. reported earnings per share of $1.84.
Enterprise value:
52.6B
EV / Invested capital:
--
Price / LTM sales:
16.32x
EV / EBIT:
198.74x
EV / Revenue:
16.39x
PEG ratio (5yr expected):
-0.60x
EV / Free cash flow:
237.65x
Price / Operating cash flow:
236.67x
Enterprise value / EBITDA:
163.88x
Gross Profit (TTM):
$2.7B
Return On Assets:
0.98%
Net Income Margin (TTM):
1.36%
Return On Equity:
31.15%
Return On Invested Capital:
1.51%
Operating Margin:
29.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.7B | $2.1B | $3.2B | $500.9M | $1.2B | |
| Gross Profit | $1.4B | $1.8B | $2.7B | $415M | $1B | |
| Operating Income | -$354.4M | -$188.1M | $264.7M | -$76.9M | $368M | |
| EBITDA | -$299.5M | -$132.1M | $321M | -$62.9M | $381.8M | |
| Diluted EPS | -$4.15 | -$2.62 | $0.24 | -$0.87 | $1.84 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.7B | $2.7B | $3B | $3.4B | $4B | |
| Total Assets | $3.5B | $3.5B | $3.8B | $4.2B | $4.9B | |
| Current Liabilities | $610.7M | $772.8M | $949.8M | $1.2B | $1.6B | |
| Total Liabilities | $2.7B | $3.6B | $4B | $4.2B | $4.6B | |
| Total Equity | $755.9M | -$67.6M | -$165.9M | $32.4M | $233.9M | |
| Total Debt | $1.9B | $2.6B | $2.6B | $2.7B | $2.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2M | $56.6M | $265.9M | $43.7M | $325.1M | |
| Cash From Investing | -$235.6M | -$304.6M | $420.6M | -$30.3M | $501.1M | |
| Cash From Financing | $196.3M | $302.4M | -$319.5M | $102.8M | -$448.3M | |
| Free Cash Flow | -$66.6M | $16.1M | $221.4M | $39.5M | $313M | |
ALNY
Sector
Market Cap
$52.6B
$28.1M
Price % of 52-Week High
80.28%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
-0.43%
-1.55%
1-Year Price Total Return
69.81%
-19.36%
Beta (5-Year)
0.325
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$399.91
200-day SMA
Buy
Level
$371.90
Bollinger Bands (100)
Sell
Level
421.88 - 470.34
Chaikin Money Flow
Buy
Level
86.7M
20-day SMA
Sell
Level
$407.68
Relative Strength Index (RSI14)
Sell
Level
38.57
ADX Line
Sell
Level
27.1
Williams %R
Neutral
Level
-52.9748
50-day SMA
Sell
Level
$434.63
MACD (12, 26)
Sell
Level
-11.69
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
155.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.9142)
Sell
CA Score
(Annual)
Level (-2.8268)
Sell
Beneish M-Score
(Annual)
Level (-1.7289)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (2.9203)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, ALNY has received 14 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ALNY average analyst price target in the past 3 months is $491.92.
-
Where Will Alnylam Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Alnylam Pharmaceuticals, Inc. share price will rise to $491.92 per share over the next 12 months.
-
What Do Analysts Say About Alnylam Pharmaceuticals, Inc.?
Analysts are divided on their view about Alnylam Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alnylam Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $310.00.
-
What Is Alnylam Pharmaceuticals, Inc.'s Price Target?
The price target for Alnylam Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $491.92 according to 21 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is ALNY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Alnylam Pharmaceuticals, Inc. is a Buy. 14 of 21 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALNY?
You can purchase shares of Alnylam Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alnylam Pharmaceuticals, Inc. shares.
-
What Is The Alnylam Pharmaceuticals, Inc. Share Price Today?
Alnylam Pharmaceuticals, Inc. was last trading at $406.32 per share. This represents the most recent stock quote for Alnylam Pharmaceuticals, Inc.. Yesterday, Alnylam Pharmaceuticals, Inc. closed at $397.83 per share.
-
How To Buy Alnylam Pharmaceuticals, Inc. Stock Online?
In order to purchase Alnylam Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ALNY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ALNY
Sector
P/E ratio
1,654.18x
24.09x
PEG ratio
-0.60x
-0.01x
P/B ratio
224.71x
1.83x
Price / LTM sales
16.32x
1.59x
Growth Metrics
ALNY
Sector
Revenue growth
149.35%
4.68%
Earnings growth
312.06%
10.88%
Revenue (5-year growth)
59.22%
6.45%
Earnings forecast
$1.72
-$0.18
Profitability
ALNY
Sector
Profitability FY 2024
$1.9B
$3.6M
Return on invested capital
1.51%
-31.87%
Return on assets
0.98%
-28.18%
Return on equity
31.15%
-37.89%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Jan
29
Balance Sheet
ALNY
Sector
Total cash
$2.7B
$26.2M
Short term investments
$1.7B
$25.7M
Total assets
$4.3B
$76.7M
Long term debt
$2.7B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
